Abstract
Abstract Prognosis and risk assessment of breast cancer patients are currently driven by TNM stage, ER/PR/HER2 expression, tumor grade and lymphovascular invasion (LVI). However there is critical need for improved biomarker assessment platforms to better predict systemic treatment response. One roadblock is the lack of semi-quantitative methods to reliably measure expression, activity and localization of biomarkers in formalin-fixed tumor specimens. The present study assesses reliability of automated IHC scoring compared to manual scoring of routine and non-routine biomarkers (HER2, cyclin D1, p53 and phospho(p)-ERK) on a human breast cancer tissue microarray according to REMARK guidelines, and correlates these markers with clinical-pathological data. Using a triplicate core TMA of formalin-fixed paraffin embedded tissues, we investigated 63 primary invasive breast cancers, for which ER/PR/HER2 status, LVI, grade and recurrence status were recorded. IHC was performed on the TMA for the above biomarkers (pH 6 citrate buffer conditions). Histologic (H) scores (% positive tumor area × staining intensity 0-3) were determined manually by two independent evaluators with resolution of discordant cases by a senior pathologist. Excellent replicability was observed between H scores for each marker compared on replicate slides, as determined by Spearman correlations (0.79-0.82). Each TMA slide was then scanned into the Ariol Imaging System, algorithms were trained for each marker, and H scores were calculated. Pearson correlation coefficients (with data left as continuous) and Kappa statistics (with dichotomized data) were used for inter-method comparisons. Associations between biomarker positivity and clinical data were assessed by Fisher's exact test. Excellent concordance between manual and automated Ariol scores was observed for all four markers based on Kappa statistics (0.667-0.813) and Pearson correlation coefficients (0.790-0.885). Distinct proportions of tumor cases showed any positive staining for membranous HER2 (19/63), nuclear p53 (16/56), cyclin D1 (26/57) and pERK (32/59). A statistically significant association of pERK positivity with absence of LVI (p=0.0025) and lymph node negativity (p=0.0006) was observed. In contrast, pERK positivity was associated with high-grade tumors (p=0.0040), consistent with a role of pERK in poorly differentiated high-grade primary tumors. p53 over-expression, characteristic of dysfunctional p53 in breast cancer, was also associated with high tumor grade (p=0.0074). Thus automated quantitation of immunostaining yields objective results that do not differ from pathologists’ scoring, and provide meaningful associations with clinico-pathological data. (Supported by CIHR, PSI, and Queen's Dept. Pathol. & Mol. Med.) Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3207. doi:10.1158/1538-7445.AM2011-3207
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
